Beta lapachone

Drug Profile

Beta lapachone

Alternative Names: ARQ 501; BRN 0181499; CO-501; NSC 26326; NSC 629749; R 1668; SL 11001

Latest Information Update: 03 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer ArQule
  • Class Antineoplastics; Eye disorder therapies; Naphthoquinones; Obesity therapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; E2F1 transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Leiomyoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 07 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections
  • 23 Jun 2006 Phase-II clinical trials in combination with gemcitabine in patients with Pancreatic cancer in USA (IV-infusion)
  • 01 May 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the pharmacokinetics, adverse events and Cancer therapeutic trials sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top